pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$INCYINCYTE CORP

$INCY120.27-0.58%
Wilmington, DE, USupdated 7h ago

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes

🐶 often sniffed alongside

top 5
  • drugretifanlimab11 co-mentions · 6 sources
  • tagApproval10 co-mentions · 5 sources
  • drugZYNYZ10 co-mentions · 5 sources
  • tagOncology6 co-mentions · 1 sources
  • tagSmall Molecule1 co-mentions · 1 sources
pipeline
11
marketed
4
phase 3
1
catalysts ytd
5
approvals ytd
1
recalls ytd
0

Pipeline(11)

pipeline depth11 products
Phase 1: 2Phase 2: 2Phase 3: 1Marketed: 4pre_registration: 1Unknown: 1
2Phase 12Phase 21Phase 34Marketed1pre_registration1Unknown
Marketed
Opzelura
Hidradenitis Suppurativa
Tyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2
Marketed
axatilimab
Graft Versus Host Disease (GVHD)
Marketed
pemigatinib
Metastatic Bile Duct Cancer
Fibroblast growth factor receptor 3Fibroblast growth factor receptor 1
Marketed
retifanlimab
Squamous Non-Small Cell Lung Cancer
Programmed cell death protein 1
Phase 3
tafasitamab
Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associat…
B-lymphocyte antigen CD19
Phase 2
ruxolitinib phosphate
Hemophagocytic Lymphohistiocytosis
Tyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2
Phase 2
zilurgisertib fumarate
Fibrodysplasia Ossificans Progressiva (Myositis Ossifican…
Phase 1
INCA-033989
Essential Thrombocythemia
Phase 1
INCB-100658
Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)
drug
ZYNYZ
1 INDICATIONS AND USAGE ZYNYZ is a programmed death recep…
Programmed cell death protein 1
pre_registration
povorcitinib phosphate
Hidradenitis Suppurativa

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Oct 27, 2026
earnings
$INCY120.27-0.58%
21d ago
INCYTE CORP earnings
INCYTE CORP
→
view all catalysts →

Active trials

  • phase2Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativarecruitingn=40
  • phase3A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinomarecruitingn=588
  • phase2A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)recruitingn=60
  • phase1Study of INCA036978 in Participants With Myeloproliferative Neoplasmsrecruitingn=218
  • phase3Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)active not recruitingn=573
  • phase1A Study to Assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB161734 in Healthy Male Participantscompletedn=10
  • phase3A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)completedn=190
  • phase3A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemiarecruitingn=426
🐶 Hiring Signal
No open roles indexed yet — view INCYTE CORP jobs →

News

no news has mentioned this company yet
identifiers
ticker
$INCY
SEC CIK
0000879169
country
US
source
sec_tickers
top tags
Oncology7Dermatology2Immunology2Asthma1DLBCL1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 3m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?